Asia Pacific Plasma Fractionation Market

Market Introduction

APAC is the fastest-growing market for plasma fractionation, and China, India, Japan, South Korea, Australia, and Rest of APAC are the major contributors to the market in this region. APAC accounted for significant market share in the global plasma fractionation market in 2021 owing to the growing interest of international players in China and India, government support in countries such as China, and advancing healthcare infrastructure. Therefore, the region holds huge potential for the plasma fractionation market players to grow during the forecast period.

The supply chain disturbances and the tremendous demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the APAC region. Preventive measures have been taken to control the spread of this pandemic. The COVID-19 pandemic has broadly affected the economies in the APAC region. Countries such as India, China, Japan, and South Korea were adversely affected by the pandemic. The socioeconomics was severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Countries such as China, Japan, Singapore, and South Korea are seeing an increased interest in clinical trials. High costs in western countries are also contributing to the flow of medical affairs outsourcing to the APAC region. To expand sales to the Asian market, pharmaceutical companies are becoming aware of new and changing regulatory environments for drugs, devices, and in-vitro diagnostics. New or improved regulations are implemented frequently in Asia, including changes in GMP standards, drug price controls, and medical device regulatory systems. Third-party guidance and advice are required as a part of any acquisition or improvement of current standards. Increasingly, third-party outsourcing service providers are playing a more significant role in supporting the associated market in APAC. However, the market is stabilized compared to the initial phases of the pandemic, owing to the control procedures, awareness among people, availability of vaccinations, and supportive government policies of the business in the related market.       

Market Overview and Dynamics

The plasma fractionation market in APAC is expected to grow from US$ 5,854.65 million in 2021 to US$ 9,433.53 million by 2028; it is estimated to grow at a CAGR of 7.1% from 2021 to 2028. The rest of APAC includes Southeast Asian countries like Singapore, Malaysia, Taiwan, Vietnam, and other countries. Several countries have made significant growth in the medical and research institutes, which, in turn, leads to the market growth of the Plasma fractionation market. Also, the increasing number of cases of diabetic-associated disorders is further driving the development of the market. For instance, according to a report published in the MDPI journal of pharmaceutics in 2020, the prevalence rate of DFU has been estimated to be 5.5%. Malaysia has been ranked as the highest diabetes case recorded in Asia, with around 3.6 million patients. By 2025, it is expected that about seven million adults will have diabetes and potentially develop DFU. Such factors will increase the demand for the plasma fractionation market.       

Key Market Segments

APAC plasma fractionation market is segmented into product, application, end user, and country. The APAC plasma fractionation market, based on product, has been segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The immunoglobulin segment is likely to hold the largest share of the market in 2021. The APAC plasma fractionation market, based on application is segmented into neurology, immunology, hematology, critical care, pulmonology, and others. In 2021, the Neurology segment is likely to hold the largest share of the market. The APAC plasma fractionation market, based on end user is segmented into hospitals and clinics, clinical research laboratories, academic institutes. In 2021, the hospitals and clinics segment is likely to hold the largest share of the market. Based on country, the APAC plasma fractionation market is segmented into Australia, China, India, Japan, South Korea, and rest of APAC. Japan held the largest market share in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the plasma fractionation market in APAC are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Bharat Serums and Vaccines Limited (BSV); Bio Products Laboratory Ltd.; CSL Limited; Grifols, S.A.; Kedrion S.p.A; Octapharma AG;

;

Reasons to buy report

• To understand the APAC plasma fractionation market landscape and identify market segments that are most likely to guarantee a strong return.
• Stay ahead of the race by comprehending the ever-changing competitive landscape for APAC plasma fractionation market.
• Efficiently plan M&A and partnership deals in APAC plasma fractionation market by identifying market segments with the most promising probable sales.
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form APAC plasma fractionation market.
• Obtain market revenue forecast for market by various segments from 2021-2028 in APAC region.

APAC

Plasma Fractionation Market

Segmentation

APAC Plasma Fractionation Market -

By Product

• Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Subcutaneous Immunoglobulin (SCIG)
• Albumin
• Coagulation Factor Concentrates
• Protease Inhibitors
• Other

APAC Plasma Fractionation Market - By

Application

• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Others

APAC Plasma Fractionation Market - By End User

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

APAC Plasma Fractionation Market - By Country

• Australia
• China
• India
• Japan
• South Korea
• Rest of APAC

APAC Plasma Fractionation Market - Company Profiles

• Bharat Serums and Vaccines Limited (BSV)
• Bio Products Laboratory Ltd.
• CSL Limited
• Grifols, S.A.
• Kedrion S.p.A
• Octapharma AG
• PlasmaGen BioSciences Pvt. Ltd
• SK Plasma

Asia Pacific Plasma Fractionation Strategic Insights

Strategic insights for the Asia Pacific Plasma Fractionation provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Plasma Fractionation Report Scope

Asia Pacific Plasma Fractionation Regional Insights

The geographic scope of the Asia Pacific Plasma Fractionation refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.